Cappelli F, Martone R, Gabriele M, et al. - Researchers compared two biomarker-based staging systems available for prognosis prediction in patients with transthyretin-related cardiac amyloidosis (ATTR-CA), focusing on predictive performance of these systems. This study involved 175 patients who received a diagnosis of ATTR-CA (133 wild-type and 42 hereditary). The participants were stratified into distinct stages using 2 systems: the first system comprised N-terminal pro–B-type natriuretic peptide (NT-proBNP) and estimated glomerular filtration rate (eGFR), and the second one involved NT-proBNP and troponin I (TnI). Findings revealed that better prognostic accuracy was afforded by a staging system using NT-proBNP and eGFR, vs one using NTproBNP and TnI, for ATTR-CA patients.